Blog

CMS’s value-based programs often look for lack: fewer infections, lower readmissions, etc. Here’s how to demonstrate non-events.

Spreadsheets are clunky and inefficient for contract tracking. Here’s how an automated platform solves those challenges.

Specialized patient data for rare disease research can be difficult to obtain. Here are the standard and emerging sources for researchers.

Rare disease researchers don’t always have the data they need for a long-term view. Here’s how teams can adapt.

Track these key performance indicators for deeper insights into a pharmaceutical product launch.

A strong relationship with a Center of Excellence can improve rare disease treatment access. Here’s how to build that connection.

Uninsured patients struggle to find financing for medications. Here’s how robust data can make the case for supporting these patients.

Underinsured and uninsured patients face considerable barriers to specialty drug access. Here’s how the right digital tools can help.

Data plays a key role in economic modeling and forecasting for rare disease treatment distribution. Here’s how.

U.S. payers consider several factors when evaluating specialty therapies for coverage — all of which benefit from better data.